Skip to main content
Premium Trial:

Request an Annual Quote

Dean Misenhimer, Ron Appel, Frédérique Lisacek

Kinematik, which sells the eNovatorsoftware solution, has named Dean Misenhimer director of marketing. 
Misenhimer will oversee KineMatik’s global marketing strategy, driving the company’s growth in the U.S. and other markets, along with responsibility for product marketing and branding of the eNovator product suite, the company said.
He joins KineMatik after 12 years in various marketing and directorial positions at EMC Corporation and Documentum. The company added, in a release, that Misenhimer has spent 14 years specifically in the content management market and has extensive experience in solution selling and working with life science firms.

Ron Appel, formerly professor at the department of structural biology and bioinformatics of University of Geneva and head of the Proteome Imaging Group at the Swiss Institute of Bioinformatics has moved full-time to Lausanne, Switzerland, where he is now SIB’s director.
Colleague Frédérique Lisacek is now leading Appel’s previous research group at SIB and University of Geneva.
Lisacek holds a masters degree in mathematics and in computer science, and has completed her Ph.D. in the application of computational methods to life sciences and has worked more than 20 years in both academic and commercial bioinformatics, Appel said in a statement.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.